

Vibiosphen is a French biotech that supports an ambitious vision : contributing to the fight against infectious disease and especially against antimicrobial resistance.

Combining our expertise and experience we are developing a new class of therapeutics : **polypeptoids**
This global project called therapeutics is ambitioning to add new serious leads to the missing world pipeline of anti infective.



Resist resistance with innovative approaches


POLYPEPTOIDS



Combination of polymers and peptides to create a hybrid peptide-like compound

Iterative process combining AI with biotechnology

AI processing



Thanks to the structure of polypeptoids and to the results of lead optimization, AI gives predictive information on relevance by adjusting hydrophobic and cationic ratio



ADDED VALUE

All the AMPs benefits without the downs

- ✓ Active against Gram negative/positive **bacteria, fungi and viruses**
- ✓ No resistance induction
- ✓ Reduction of side-effects
- ✓ **Evolutive polypeptoid library**
- ✓ **Polypeptoids** production is simple and **cost effective**



Robin DUMAS, Chief Business Innovation Officer
Mobile : +33 782 727 623
Robin.dumas@vibiosphen.com

Patricia MARTIN, Chief Scientist Officer
Phone : +33 561 287 034
Patricia.Martin@vibiosphen.com